Navigation Links
Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Date:6/12/2008

WALTHAM, Mass., June 12 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the fourth quarter and fiscal year 2008, ended March 31, 2008. Total revenue for fiscal year 2008 was $19,296,000 compared to total revenue of $14,074,000 for fiscal year 2007 ended March 31, 2007, an increase of $5,222,000 or 37%. Total revenue for the year consisted primarily of Protein A and SecreFlo(R) product revenue.

Operating expenses for fiscal year 2008, excluding the $40,170,000 net gain from litigation previously reported in our second quarter as a result of our settlement with ImClone Systems, Inc., were $23,574,000 compared to $15,900,000 in fiscal year 2007. The increase in operating expenses of $7,674,000 was primarily the result of legal expenses incurred in conjunction with both the ImClone Systems, Inc. and Bristol-Myers Squibb litigations, direct material expenses associated with the increase in revenue, and increased research and development spending.

Net income for the year was $37,107,000 or $1.18 per diluted share, compared to a net loss for fiscal 2007 of $889,000 or $0.03 per diluted share. Net income includes a net gain of $40,170,000 from the litigation settlement with ImClone during the second quarter of fiscal year 2008. Cash and marketable securities as of March 31, 2008 were $60,589,000 compared to $22,627,000 as of March 31, 2007.

"During the past year, we have successfully advanced our product pipeline, achieved strong revenue growth and settled our outstanding litigations with ImClone Systems, Inc. and Bristol-Myers Squibb, resulting in substantial new resources for the company," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "Our f
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
2. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
3. Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
4. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
5. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
6. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
7. Cord Blood America Reports CorCell, Its Major Acquisition in 2006, Turns Profitable
8. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
9. Rosetta Genomics Reports First Quarter 2008 Financial Results
10. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
11. Advance Nanotech Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that the ... PVM technology , is now available. The new ... continuously captures high-resolution images under a wide range ... a report pairing the most relevant images to ... compelling blend of high resolution images and trend ...
(Date:12/15/2014)... -- Origin Agritech Limited (NASDAQ GS: SEED) (" Origin ", or ... in China , today announced that the ... September 30, 2014, before the market opens on Thursday, January ... on January 8, 2015, at 8:00 a.m. ET / 9:00 ... results. To participate in the call, please dial +1-888-346-8982 in ...
(Date:12/13/2014)... Maryland (PRWEB) December 12, 2014 Clarassance, ... today announced its new name: Therabron Therapeutics , ... therapy and bronchioles (a type of structure in the ... the company’s mission to develop novel protein therapeutics for ... of directors decided to change the name to mark ...
(Date:12/13/2014)... 13, 2014 According to population studies: ... between now and 2030." If a population explosion like ... most populous state in the country. , To that ... the Future of North Carolina Forum on December 16th ... have the necessary infrastructure in place? Enough clean water? ...
Breaking Biology Technology:New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2
... Anticipating a catastrophic increase in Alzheimer,s disease and related ... Plan for Alzheimer,s disease, a disease estimated to double ... a 10-year course of action with guiding principles, goals ... crisis.   Alzheimer,s will soon soar to ...
... 2011 GlobalCare Clinical Trials, Ltd, (GlobalCare) today ... selected clinical study visits at convenient locations – ... – for study patients to support phase I-IV ... and personalized medicine in all age groups. GlobalCare,s ...
... Inc. (NYSE Amex: PTN ) announced that it ... Stock Conference on Tuesday, March 15, 2011, at 12:00 p.m. ... Carlton Laguna Niguel in Dana Point, CA. ... Technologies, will provide an update on Palatin,s corporate and development ...
Cached Biology Technology:California Leaders Confront Alarming Rise in Alzheimer's Cases 2California Leaders Confront Alarming Rise in Alzheimer's Cases 3GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 2GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 3GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 4
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
(Date:11/18/2014)... Nov. 18, 2014  The Secure Identity & ... today jointly announce the formation of The Airport ... its Identity and Biometric Entry and Exit ... received official support from BORDERPOL, the international non-profit ... and provide expertise regarding border security, traveler and ...
(Date:11/12/2014)... Nov. 12, 2014 Crossmatch™, a leading provider ... U.are.U ® fingerprint readers have been deployed throughout ... Central Mexico . The bakery chain implemented ... payroll issues caused by employees clocking in for each ... fingerprint readers, Montparnasse relied on paper timecards and a ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... Researchers at the University of Michigan Comprehensive Cancer Center ... treat multiple types of cancer. A study, published this ... that AT-406 effectively targets proteins that block normal cell death ... while not harming normal cells. The researchers believe the drug ...
... 29, 2011)Uterine fibroid embolizationan interventional radiology treatment for ... in the muscular wall of the uterusimproves a ... are specifically caused by those fibroids, confirm researchers ... Scientific Meeting in Chicago, Ill. "Uterine fibroid ...
... formulation of antioxidants taken orally before imaging with ionizing ... of Interventional Radiology,s 36th Annual Scientific Meeting in Chicago, ... clinical trial of its kind, as much as a ... administering the formula prior to CT scans. "In ...
Cached Biology News:New cancer drug discovered at U-M heads to clinical trials 2Fibroids cause women's lower urinary tract problems: uterine fibroid embolization helps 2Fibroids cause women's lower urinary tract problems: uterine fibroid embolization helps 3Antioxidant formula prior to radiation exposure may prevent DNA injury 2